GNLX: Genelux Corporation Stock

by  •  • Comments Off on GNLX: Genelux Corporation Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 101.24
Enterprise Value ($M) 91.82
Book Value ($M) 19.47
Book Value / Share 0.74
Price / Book 5.20
NCAV ($M) 15.78
NCAV / Share 0.60
Price / NCAV 6.41

Profitability (mra)
Return on Invested Capital (ROIC) -1.29
Return on Assets (ROA) -1.94
Return on Equity (ROE) -10.52

Liquidity (mrq)
Quick Ratio 3.69
Current Ratio 3.69

Balance Sheet (mrq) ($M)
Current Assets 24.20
Assets 27.89
Liabilities 8.42
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.17
Operating Income -24.16
Net Income -28.30

Cash Flow Statement (mra) ($M)
Cash From Operations -20.27
Cash from Investing -14.72
Cash from Financing 44.02

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-02 13G Szalay Aladar 15.70
06-20 13G Parrott Billy James 8.70

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 45,292 116,844 38.76
2024-05-02 46,379 35,597 130.29
2024-05-01 64,332 42,762 150.44
2024-04-30 29,181 46,761 62.40
2024-04-29 44,973 34,656 129.77

(click for more detail)

Similar Companies
GLMD – Galmed Pharmaceuticals Ltd. GLSI – Greenwich LifeSciences, Inc.
GLTO – Galecto, Inc. GNPX – Genprex, Inc.
GOVX – GeoVax Labs, Inc.


Financial data and stock pages provided by
Fintel.io